Search results for "Mother"

showing 10 items of 2331 documents

Spinal Intradural Intramedullary Dissemination in the Absence of Intracranial Relapse of a Previously Radically Treated Temporal Lobe Glioblastoma Mu…

2017

Intracranial glioblastoma multiforme (GBM) constitutes the most frequent and unfortunately aggressive primary central nervous system malignancy. Despite the high tendency of these tumors to show local relapse within the brain after primary therapy, dissemination into the spinal axis is an infrequent event. If spinal metastases occur they are leptomeningeal in the vast majority of cases and always in the context of intracranial progressive disease. Spinal intramedullary metastases of intracranial GBM have rarely been described to date. We report the unique case of a young woman with subacute progressive paraparesis due to spinal intramedullary metastases of a temporal lobe GBM despite the re…

medicine.medical_specialtyPathologymedicine.medical_treatmentCentral nervous systemSpinal intradural intramedullary disseminationContext (language use)Case ReportMalignancylcsh:RC254-282Temporal lobelaw.inventionIntramedullary rod03 medical and health sciences0302 clinical medicinelawmedicineChemotherapybusiness.industrymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.anatomical_structureOncology030220 oncology & carcinogenesisTemporal lobe glioblastoma multiformeRadiologybusiness030217 neurology & neurosurgeryProgressive diseaseGlioblastomaCase Reports in Oncology
researchProduct

Docetaxel as Salvage Therapy in Highly Pretreated and Drug Resistant Gastrointestinal Carcinomas

2008

Introduction Despite many efforts to develop new chemotherapies for metastatic upper gastrointestinal (GI) cancer, overall prognosis continues to be fatal, particularly in gastric and pancreatic cancer. Many of these patients deserve second-or third-line treatment after failure of first-line chemotherapy. Therefore, we analysed toxicity and response rate of weekly docetaxel after failed upfront regimes in these upper GI cancer patients. Patients and Methods Between 2001 and 2006, 18 patients received docetaxel based regimes (35 mg/m2 weekly) after informed consent. Response rates were determined using RECIST criteria or tumor progression if clinically evident. Toxicities were graded based o…

medicine.medical_specialtyPathologymedicine.medical_treatmentSalvage therapyNeutropeniachemotherapygastriclcsh:RC254-282GastroenterologysalvageInternal medicinePancreatic cancermedicinedocetaxelOriginal ResearchChemotherapyLeukopeniabusiness.industryCancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasemetastaticRegimenOncologyDocetaxelmedicine.symptombusinessmedicine.drugClinical medicine. Oncology
researchProduct

Deflazacort in Duchenne dystrophy: Study of long-term effect

1994

A randomized double-blind controlled trial of deflazacort was conducted in 28 Duchenne muscular dystrophy patients either treated with deflazacort 2.0 mg/kg alternate-day therapy or placebo. The deflazacort group showed significant improvement in climbing stairs (P < 0.01), in rising from a chair, Gower's maneuver, and walking (P < 0.0025) after 6 months of treatment. After 1 year, all the above changes remained significantly improved and the MRC index was significantly better (P < 0.05) in the treated group. After 2 years, a significant change was found in the MRC index: higher scores in walking, chair rising (P < 0.02), and grade and time of Gower's maneuver (P < 0.05) were found. The mea…

medicine.medical_specialtyPatient DropoutsTime Factorsmedicine.drug_classPhysiologyDuchenne muscular dystrophymedicine.medical_treatmentMotor ActivityPlaceboMuscular Dystrophieslaw.inventionCellular and Molecular NeuroscienceDouble-Blind MethodRandomized controlled trialPregnenedioneslawPhysiology (medical)medicineHumansChildGaitChemotherapybusiness.industryMusclesAnti-Inflammatory Agents Non-SteroidalBody Weightmedicine.diseaseSurgeryClinical trialDeflazacortAnesthesiaCorticosteroidNeurology (clinical)medicine.symptombusinessWeight gainFollow-Up Studiesmedicine.drugMuscle &amp; Nerve
researchProduct

Reconstruction of vertebral body after radiofrequency ablation and augmentation in dorsolumbar metastatic vertebral fracture: Analysis of clinical an…

2017

Background: Painful spinal metastases usually occur in malignant neoplastic disease. Treatment for bone metastases has been largely conservative, and it includes the use of high doses of analgesics, radiotherapy, chemotherapy, hormone therapy, and bisphosphonates; however, results are sometimes transient and ineffective. In the presence of neurological involvement a surgical strategy should be considered. Recently, percutaneous procedures such as radiofrequency ablation, vertebroplasty, and kyphoplasty have been introduced as palliative techniques to treat painful vertebral metastases [3, 11, 25]. Methods: In our study we combined the use of radiofrequency ablation with vertebroplasty in th…

medicine.medical_specialtyPercutaneousRadiofrequency ablationmedicine.medical_treatment030218 nuclear medicine & medical imaginglaw.invention03 medical and health sciences0302 clinical medicinelawmedicineMinimally invasive spinal surgeryChemotherapyVertebroplasty.business.industrySettore MED/27 - NeurochirurgiaRadiofrequency ablationSurgeryVertebral bodyRadiation therapy030220 oncology & carcinogenesisRadiological weaponSpinal metastaseRadiologyHormone therapyVertebral fracturebusinessSpinal metastases
researchProduct

Cytoreductive surgery and mitomycin C hyperthermic intraperitoneal chemotherapy with CO2 recirculation (HIPEC-CO2) for colorectal cancer peritoneal m…

2021

Peritoneal dissemination from colorectal cancer (CRC) has long been associated with unfavorable prognosis. However, in the last decades, the combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was able to obtain up to 30% 5-year survival rate in selected centers. Despite the wide diffusion of CRS and HIPEC, until now, there are no clear recommendations on the drug of choice for HIPEC nor its technique, and safety and efficacy data of HIPEC regimens and techniques are lacking. We performed a retrospective analysis of a prospectively maintained database of 26 CRS and mitomycin C HIPEC with CO2 recirculation (HIPEC-CO2) for CRC peritoneal metastasis…

medicine.medical_specialtyPeritoneal metastasisColorectal cancerMitomycinSettore MED/18 - CHIRURGIA GENERALE2Hyperthermic Intraperitoneal Chemotherapy030230 surgery03 medical and health sciences0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansHyperthermiaAdverse effectSurvival ratePeritoneal NeoplasmsRetrospective StudiesCarcinomatosisHIPECbusiness.industryInducedMitomycin CCommon Terminology Criteria for Adverse EventsCytoreduction Surgical ProceduresHyperthermia InducedCarbon DioxidePrognosismedicine.diseaseColorectal cancerCombined Modality TherapyHIPEC-COSurgerySurvival Rate030220 oncology & carcinogenesisPeritoneal metastasisSurgeryHyperthermic intraperitoneal chemotherapyColorectal NeoplasmsbusinessCytoreductive surgeryUpdates in Surgery
researchProduct

Treatment of relapsing idiopathic nodular panniculitis (Pfeifer-Weber-Christian disease) with mycophenolate mofetil

1998

Idiopathic nodular panniculitis (Pfeifer-WeberChristian disease) is characterized by fever and symmetric subcutaneous nodules often located on the lower extremities.1,2 Histologically, a lobular panniculitis with a pronounced neutrophilic infiltrate is observed. The course of the disease is characterized by acute onset with fever and malaise and the simultaneous appearance of painful subcutaneous nodules. Some patients experience involvement of the intra-abdominal or retroperitoneal fat. Relapses are frequent, and a fatal outcome has been described repeatedly. Therapy usually consists of steroids in medium to high dosages, as well as immunosuppressive drugs such as azathioprine or methotrex…

medicine.medical_specialtyPrednisolonemedicine.medical_treatmentAzathioprineDermatologyWeber–Christian diseaseMycophenolic acidMalaiseRecurrencemedicineHumansGlucocorticoidsChemotherapybusiness.industryMiddle AgedMycophenolic Acidmedicine.diseaseDermatologySurgeryPanniculitis Nodular NonsuppurativeSubcutaneous nodulePrednisoloneFemalemedicine.symptombusinessPanniculitisImmunosuppressive Agentsmedicine.drugJournal of the American Academy of Dermatology
researchProduct

Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?

2021

Pharmacogenetics is one of the cornerstones of Personalized Precision Medicine that needs to be implemented in the routine of our patients’ clinical management in order to tailor their therapies as much as possible, with the aim of maximizing efficacy and minimizing toxicity. This is of great importance, especially in pediatric cancer and even more in complex malignancies such as neuroblastoma, where the rates of therapeutic success are still below those of many other types of tumors. The studies are mainly focused on germline genetic variants and in the present review, state of the art is presented: which are the variants that have a level of evidence high enough to be implemented in the c…

medicine.medical_specialtyQH301-705.5Antineoplastic AgentsReviewchemotherapyPediatricsCatalysisInorganic ChemistryNeuroblastomadrug labelQuimioteràpiamedicineHumansMedical physicsBiology (General)Precision MedicinePhysical and Theoretical Chemistryclinical implementation guidelinesQD1-999SNP (single nucleotide polymorphism)Molecular BiologySpectroscopybusiness.industryOrganic ChemistryGenetic variantsGeneral MedicineEvidence-based medicinePrecision medicinePediatric cancerComputer Science ApplicationsChemistryPharmacogeneticsFarmacogenèticabusinessPharmacogenetics
researchProduct

Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin: A Single Center Experience.

2021

Background: Pseudomyxoma peritonei (PMP) originating from appendiceal mucinous neoplasm is a rare peritoneal malignancy characterized by the progressive intraperitoneal accumulation of mucus leading to death if left untreated. In recent years, cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) offered increased survival rates. This study aims to identify the clinical, pathological, and surgical features influencing safety and survival outcomes of patients undergoing CRS and HIPEC for PMP of appendiceal origin.Methods: A retrospective analysis of all patients undergoing CRS and HIPEC for PMP of appendiceal origin from January 2015 to May 2019 was cond…

medicine.medical_specialtyRD1-811HIPECbusiness.industrymedicine.diseaseSingle Centerhyperthermic intra peritoneal chemotherapyGastroenterologypseudomixoma peritoneiOxaliplatinRegimenperitonectomy procedureInternal medicinemedicinePeritoneal Cancer IndexAdenocarcinomaPseudomyxoma peritoneicytoreductive surgeryHyperthermic intraperitoneal chemotherapySurgerybusinessSurvival ratemedicine.drugOriginal ResearchFrontiers in surgery
researchProduct

Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis

2020

AbstractObjectiveThe randomized, controlled MAINRITSAN2 trial was designed to compare the capacity of an individually tailored therapy [randomization day 0 (D0)], with reinfusion only when CD19+ lymphocytes or ANCA had reappeared, or if the latter’s titre rose markedly, with that of five fixed-schedule 500-mg rituximab infusions [D0 + D14, then months (M) 6, 12 and 18] to maintain ANCA-associated vasculitis (AAV) remissions. Relapse rates did not differ at M28. This ancillary study was undertaken to evaluate the effect of omitting the D14 rituximab infusion on AAV relapse rates at M12.MethodsMAINRITSAN2 trial data were subjected to post-hoc analyses of M3, M6, M9 and M12 relapse-free surviv…

medicine.medical_specialtyRandomizationAntigens CD19Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGastroenterologyDisease-Free SurvivalDrug Administration ScheduleAntibodies Antineutrophil CytoplasmicMaintenance Chemotherapylaw.invention03 medical and health sciences0302 clinical medicineRheumatologyMaintenance therapyRandomized controlled triallawInternal medicinePost-hoc analysismedicineHumansPharmacology (medical)030212 general & internal medicineSurvival rate030203 arthritis & rheumatologybusiness.industrymedicine.diseaseAntirheumatic AgentsRituximabRituximabMicroscopic polyangiitisGranulomatosis with polyangiitisbusinessmedicine.drugRheumatology
researchProduct

Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the…

2022

Abstract Objectives To assess the toxicity patterns and effectiveness of doublet chemotherapy when administered at reduced doses of 20% (FOLFOX or FOLFIRI) in combination with anti-EGFR antibodies (cetuximab or panitumumab) in old, vulnerable patients with metastatic colorectal cancer (mCRC). Patients and methods We performed a retrospective observational study of RAS and BRAF wild-type, vulnerable patients aged ≥70 years with previously untreated mCRC. The primary endpoint was safety, and secondary endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results One hundred and eighteen patients were collected from 14 selected Italian centres.…

medicine.medical_specialtyReduced doseColorectal cancerLeucovorinCetuximabNeutropeniaGastroenterologyFOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansPanitumumabDoublet chemotherapyAnti-EGFRAgedCetuximabMetastatic colorectal cancerRectal Neoplasmsbusiness.industryPanitumumabAnti-EGFRs Doublet chemotherapy Metastatic colorectal cancer Reduced doses Vulnerable older patientsExanthemamedicine.diseaseRashVulnerable older patients.OncologyColonic NeoplasmsFOLFIRIFluorouracilGeriatrics and Gerontologymedicine.symptomColorectal Neoplasmsbusinessmedicine.drugJournal of Geriatric Oncology
researchProduct